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ABSTRACT 19 
The 100,000 Genomes Project (100kGP) - a hybrid clinical-research initiative - was set up to 20 
analyse whole genome sequences (WGS) from patients living with a rare disease or cancer. 21 
The project positioned participant consent as being of central importance, but consent in the 22 
context of genomic testing raises challenging issues. In this mixed-method study, we surveyed 23 
1,337 100kGP participants regarding their experiences of taking part in the project and 24 
conducted in-depth interviews with 24 survey respondents to explore these findings further. 25 
Survey responses were analysed using descriptive statistics and interview data were analysed 26 
thematically. The consent approach of the 100kGP resulted in a proportion of our study’s 27 
participants not understanding the complexities of the project and what types of results they 28 
might receive; for example, 20% of participants in the cancer arm did not recall what decisions 29 
they had made regarding additional findings. It is not surprising that a project such as this, with 30 
such diverse aims and participant groups, would throw up at least some challenges. However, 31 
participants reported being satisfied with their experience of the project to date. Our study 32 
highlights that in the context of consent for more complex endeavours, such as the 100kGP, it                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   33 
is important to assess (and document) an agreement to take part, but complicated decisions 34 
  2 
about what and when to communicate may need revisiting over time in response to changing 35 
contexts. We discuss the implications of our findings with reference to participants of the 36 
100kGP and the newly formed NHS Genomic Medicine Service. 37 
Keywords: Consent, genomics, 100,000 Genomes Project. 38 
 39 
INTRODUCTION 40 
The 100,000 Genomes Project 1 (100kGP) was a hybrid clinical-research initiative set up to 41 
sequence whole genomes from National Health Service (NHS) patients initially in England, 42 
but later extended to include Wales, Scotland and Northern Ireland. The project aimed to find 43 
molecular genetic diagnoses for people affected by rare conditions, as well as to improve 44 
treatment and outcomes for people with cancer. Identifying the genetic cause of a suspected 45 
rare disease, or improved treatment for someone with cancer were the ‘main findings’ to be 46 
provided to participants. Participants could also opt to receive ‘additional findings’ (AFs) and 47 
carrier testing, the results of which are still to be released. AFs are selected genetic risk factors 48 
that predispose for serious conditions, for which screening and/or treatment are usually 49 
available. The list of AFs looked for is still subject to change, as evidence evolves, but currently 50 
includes various cancer predisposition syndromes and familial hypercholesterolaemia(1). The 51 
NHS Genomic Medicine Service has been set up in England with similar aims and 52 
infrastructure to the 100kGP, though AFs will not initially be included(2). Through this new 53 
service whole-genome sequencing (WGS) will become a routine and frontline test in cross-54 
cutting areas of medicine(3). 55 
 56 
 
1 For more details regarding the 100kGP please visit www.genomicsengland.co.uk/about-genomics-
england/the-100000-genomes-project/ 
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The 100kGP framed participant consent as being of central importance (See Figure 1 for 57 
100kGP consent process). Indeed, one of its four main aims was ‘to create an ethical and 58 
transparent programme based on consent’(4). Consent in the context of genomic testing has 59 
long been seen as a challenging issue and more so with the hybrid nature of the 100kGP, where 60 
research and clinical elements were combined in the consent approach. The detailed but 61 
unfocussed approach of genome sequencing, and its familial nature, means that results can be 62 
hard to accurately forecast and might be unexpected, or may have ramifications for others 63 
beyond the person being tested(5).  64 
 65 
Research ethics committees tend to place great weight on the importance of consent, partly in 66 
reaction to previous scandals where research participants have been lied to or kept unaware of 67 
important information(6). Clinical practice also elevates information provision during the 68 
consent process as the central method by which respect is shown for patient autonomy(7). The 69 
many uncertainties that surround genomics(8) make specific consent hard to achieve, and 70 
correspondingly, 100kGP participants were at some points asked to make broad rather than 71 
specific decisions; for example, they could decide whether to receive AFs or not, but they could 72 
not pick and choose what these AFs might be(1). 73 
[Figure 1 here] 74 
We undertook a mixed method study: in that we used a survey to generate quantitative data 75 
regarding participants’ recollections of the consent process for the 100kGP, and then explored 76 
the insights gained from the survey data more deeply with subsequent qualitative interviews 77 
which aimed to elicit how and whether consent for genomic testing appeared to be working in 78 
practice. This forms part of a wider study involving interviews with patients(9) and focus 79 
groups with health professionals(10) regarding views on consent and confidentiality in relation 80 
to genetic information.  81 
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 82 
MATERIALS AND METHODS 83 
This study used a survey followed by in-depth interviews with a subset of survey respondents 84 
[Figure 2], aiming to further explore the findings of the survey and capitalise on the strengths 85 
of both qualitative and quantitative data in order to enhance the robustness of our 86 
conclusions(11). Ethics approval was obtained from the NHS South Central Hampshire 87 
Research Ethics Committee (reference number 13/SC/0041). 88 
[Insert figure 2 here] 89 
Development of survey and interview schedule 90 
We developed initial survey questions based on a review of the extant literature about ethical 91 
issues in genomics (see supplementary information for survey questions). Co-authors discussed 92 
each question and reached a consensus about which to keep. Discussion focused on whether 93 
the proposed questions were likely to elicit meaningful data about the consent approach in the 94 
context of the 100kGP(12). In this paper we have focused on a selection of questions from the 95 
survey and reported interview data that linked to these questions, focusing on expectations 96 
regarding results, AFs, and familial communication.  97 
 98 
Recruitment 99 
We recruited participants through one Genomic Medicine Centre (GMC), which comprised 100 
nine NHS trusts and served 3.5 million people. Participants were NHS patients with a rare 101 
disease, their families (often patient’s parents, but sometimes other affected family members), 102 
and patients with cancer. Health professionals (HPs) and research staff recruiting participants 103 
to the 100kGP handed out our survey to all participants who consented to take part in the 104 
100kGP with an accompanying information sheet that explained the purpose of the research. 105 
Respondents either completed the survey at that time or completed it later and then returned it 106 
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by post. In line with guidelines from the UK Health Research Authority(13), we inferred 107 
participant consent on receipt of a completed survey.  108 
 109 
We have recruited 1,819 participants to the survey study in total. However, early in the course 110 
of the study, we revised the survey, and in this paper we report on the revised survey only, 111 
which was completed by 1,337 participants. Recruitment for the revised version of the survey 112 
took place from January 2017 to October 2018 with a response rate of 60% (the GMC recruited 113 
3,088 people to the 100kGP during this period, of whom 28% (n 865) were <18 and so not 114 
eligible to receive a survey). The survey contained an expression of interest slip regarding the 115 
interview study and participants could choose to fill this in to indicate their willingness to be 116 
interviewed. Forty-two percent (n 562) of survey responders expressed an interest in being 117 
interviewed. Of interested survey responders a purposeful sample of 10% (n 54), which 118 
included participants from a range of conditions, ages, and gender, were contacted by email or 119 
telephone. Of these, 24 were interviewed between May 2017-April 2018 (24 did not respond 120 
to email or phone contact, and a suitable date could not be found for 6). If they wished to 121 
proceed, a mutually convenient time and place was arranged. If participants came to the 122 
hospital, they were offered compensation for their travel and parking. All interviews were 123 
conducted by LB, who has a health psychology background and previous experience of 124 
interviewing people living with genetic conditions. 125 
 126 
Data analysis  127 
Interviews were transcribed and analysed thematically(14). We generated codes from the first 128 
few transcripts and used these to guide the coding of all transcripts; codes were added to the 129 
analysis as subsequent transcripts were analysed. Codes were organised into categories and 130 
then refined into two overarching themes. We considered each of these themes considering our 131 
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survey data. NVIVO (QSR International, v11.4.3 (2084) for Mac) was used to organise and 132 
manage the qualitative data and SPSS to conduct descriptive statistics for the survey data. No 133 
surveys were removed from the analysis if some data were missing so figures in results do not 134 
always total 100%. 135 
 136 
RESULTS 137 
Demographics 138 
We surveyed and interviewed respondents from a range of ages, genders, and education levels 139 
- Table 1 shows the participant demographics.  Overall, 70% of participants came from the 140 
‘rare disease’ arm of the 100kGP, reflecting the 74% of rare disease participants recruited by 141 
the GMC in total. A higher proportion of women were interviewed than men; we attempted to 142 
redress this but were unsuccessful (see Table 2 for a comprehensive account of the survey 143 
results). 144 
[Insert table 1 here] 145 
[Insert table 2 here] 146 
The following expands on our two themes. 147 
 148 
1. “I don’t remember, maybe I didn’t understand it completely”  149 
This theme describes some participants’ struggle to call to mind the nature of the decisions 150 
they had been asked to make; the various misconceptions they held about the project; and that 151 
many were unaware of key implications of the project, for example the potential relevance for 152 
family members, or the likelihood of finding a diagnosis. 153 
[Insert table 3 here] 154 
Not all participants could recollect what decisions they had taken regarding whether to have 155 
AFs. This was more common in participants in the cancer arm of the project of whom 20% 156 
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(n=67) were ‘not sure’ if they had consented to have AFs, relative to only 5% (n=49) of rare 157 
disease participants. However, interview data suggested that poor recollection of decisions was 158 
perhaps more common than indicated by the survey as in some cases it became clear to the 159 
interviewer that a participant did not remember making a decision about AFs, despite indicating 160 
in the survey that they had chosen to find out about them (Table 3, quote 1). When these 161 
inconsistencies were pointed out to the participants, they appeared unconcerned. 2 162 
 163 
We asked participants about their recollections regarding the nature of AFs. Over two thirds of 164 
all survey participants (72%, n=755) thought that AFs would tell them about ‘all kinds of 165 
possible risks’. The 100kGP restricted AFs to a few select genomic variants known to 166 
predispose to serious conditions, for which treatment and/or screening is likely to be helpful. 167 
Less than 1% of participants are expected to have an AF under the current list 3 and the 100kGP 168 
participant information sheets stated that ‘The diseases we look for are uncommon, and the 169 
chance of you having one of them is low’(15). 170 
 171 
Of those interview participants who did remember providing consent for AFs, many had 172 
misunderstood what this information would tell them (table 3, quote 2). Interview participants 173 
thought that AFs may tell them about their risk of developing conditions like arthritis, 174 
Huntington’s, brain cancer and Parkinson’s, none of which are being searched for by the 175 
100kGP. A few participants reported that they believed AFs would tell them about conditions 176 
that they already had, or those that would need “immediate attention” (P9 Rare Disease). The 177 
100kGP participant information stated that the project might ‘find something which could be 178 
important for the health of your family’(15); and we asked questions about the familial 179 
 
2 The researcher alerted the 100kGP team if a discrepancy was found and the team contacted the participant. 
3 As yet, no AFs have been reported to participants. 
  8 
implications of participating. Our survey found that over three-quarters of participants (77%, 180 
n=997) reported that they had told their family members they were taking part in the project, 181 
whereas less than two thirds (62%, n=737) had told those family members that AFs might be 182 
found as well as a main finding.  183 
 184 
We explored this further during interviews, where some participants discussed how it had not 185 
occurred to them to inform their relatives (Table 3, quote 3-4). Some did not understand why 186 
their results would be relevant to their relatives and thought AFs were personal to them: “I 187 
think the additional is probably more personal to me isn’t it?” (P6 Rare Disease Parent). Some 188 
interview participants explained that they intended to inform relatives but had not “through 189 
lack of opportunity” (P17 Rare Disease Parent) or plan to “if something [an AF] comes out” 190 
(P14 Cancer). Also, many indicated that the people that they chose to talk to about the project 191 
were not blood relatives for whom the project might find medically relevant information, but 192 
unrelated family members whose support and opinion was important (Table 3, quote 5).  193 
 194 
We asked questions about the likelihood that they or their family members would receive a 195 
diagnosis through the 100kGP. Participants tended to hold optimistic views about what they 196 
would get from the project. Over half of survey participants (62%, n=693) thought that it was 197 
likely (48%, n=533) or very likely (14%, n=160) that they, or their family member, would 198 
receive a diagnosis. In contrast, the 100kGP report on their website that an estimated 20-25% 199 
of participants will receive a diagnosis,(15) though this was not included in the information 200 
sheets or consent forms. 201 
 202 
2. “I don’t remember much, and I don’t understand everything, but that’s OK”  203 
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This theme describes how many participants seemed unconcerned that they could not 204 
recollect some details of what they consented to – they trusted that HPs, and the project, 205 
would act in their interests. 206 
[Insert table 4 here] 207 
As survey data showed that some participants did not recall the decisions they had made and 208 
had not understood certain aspects of the project, we explored this with interview participants. 209 
Participants were aware that they could not remember everything; they may have remembered 210 
certain aspects, but rarely the details. What they did report was that they felt satisfied with the 211 
consent process and had been given enough information to make a decision about whether or 212 
not to participate and have AFs looked for (Table 4, quote 1).  213 
 214 
Interviewees did not think the project was particularly complicated. When asked about the 215 
consent process, and if anything could have been made clearer, many said the project was 216 
clearly explained, made sense, and was ‘straightforward’. Trust appeared to play a part in why 217 
participants took the decision to participate, a finding also reported in other studies(16-20). 218 
Participants were not worried about the technicalities and trusted that the researchers would 219 
use their data responsibly (Table 4, quote 2), with the number of documents they received 220 
enhancing the perception of thoroughness and reliability (Table 4, quote 3). We specifically 221 
asked interview participants if they had concerns about their data being held electronically and 222 
all but one indicated they had no worries. The participant who did have concerns had made the 223 
decision to participate regardless as they felt that the potential benefits of participating 224 
outweighed these concerns (Table 4, quote 4). Participants put aside any concerns they had and 225 
put themselves in the hands of the expert: “You have to trust these people. They’ve spent years 226 
in training […] you have to put it [trust] into the HPs” (P10 Cancer), with some participants 227 
feeling happy to sign the consent form before their HP felt comfortable to let them do so (Table 228 
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4, quote 5). The view that the project was trustworthy appeared to stem from several sources, 229 
for example participants attributed certain qualities to the project, such as not revealing 230 
information to insurance companies (Table 4, quote 6); written information about the project 231 
(Table 4, quote 7); investment in adjunct social research (Table 4, quote 8); positive past 232 
experience of the NHS (Table 4, quote 9); and specific mechanisms to preserve confidentiality 233 
(Table 4, quote 10). 234 
 235 
Some participants were aware that they might be contacted in the future – after they had 236 
received their ‘main result’, since researchers would continue to look at their data and new 237 
evidence might emerge. These participants felt more relaxed about not being able to recall 238 
decisions, or understand exactly what results they would get, because they assumed this would 239 
be revisited in the future if necessary (Table 4, quote 11). Other participants assumed that an 240 
initial result letter was all that they would receive, and thought, wrongly, that their letter 241 
relating to ‘main findings’ meant that AFs had been checked for too (Table 4, quote 12). 242 
 243 
DISCUSSION 244 
In this mixed method study, we found that many participants in the 100kGP did not always 245 
remember the decisions they were asked to make during the consent process. They also had 246 
various misconceptions about what sort of results they might receive from the project and, in 247 
some cases, were unaware that the project might find health information relevant for their wider 248 
family. Participants tended to have an optimistic view of the likelihood of finding a diagnosis 249 
via the 100kGP, and most felt satisfied with their decision to participate, even when they were 250 
made aware that the decisions they appeared to take during the consent process were different 251 
to what they thought. Our study demonstrates that many participants do not appear to have 252 
given consent to take part in the 100kGP based on scrutinising and weighing up the large 253 
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volumes of information provided by the 100kGP, but instead because they trusted the HP that 254 
suggested that they consider taking part, and trusted the project itself(20). However, some 255 
participants may have been strongly weighted towards participating to be able access 256 
technological advances they (or their children) would not otherwise be offered. It is possible 257 
they felt ‘coerced by circumstance’ and had to put aside any concerns they may have; as one 258 
participant explained “If you had told me that you were going to sell my information to the 259 
Russians, then I probably would have still done it” (P6 Rare Disease Parent). 260 
 261 
Facilitating decision-making during consent conversations 262 
Our study has important implications for future practice regarding how patients’ consent is 263 
sought for genomic testing - especially considering the complexity hybrid clinical-research 264 
endeavours introduce - and what weight is subsequently attributed to the decisions taken during 265 
an initial consent conversation. The 100kGP approach, with its strong emphasis on 266 
comprehensive written information and lengthy consent consultations, clearly engendered trust 267 
in participants and was viewed positively, but perhaps because of functions other than 268 
information provision. The number of documents participants received may have enhanced the 269 
perception of thoroughness and reliability, acting like “symbolic tokens” (17, pg 2220) of 270 
legitimacy and trustworthiness. Whilst recent court cases have tended to focus on the adequacy 271 
of information provision (e.g. Montgomery 4), provision of information is only part of the 272 
consent process. Dickert et al argue that consent is richer than respecting patient autonomy, 273 
recall of information and signing a form(21). Our study supports this, finding that the consent 274 
 
4 The Montgomery ruling (2015) established that it is not for a medical professional to decide what information 
to provide to a patient. Instead health professionals need to provide information that a reasonable patient would 
want to know as well as what the particular patient in question wants to know. The medical professional is or 
should reasonably be aware that the particular patient would be likely to attach significance to a risk of injury in 
treatment. 
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approach in the 100kGP encompassed additional ethically important functions, such as 275 
reinforcing trust. 276 
 277 
Our data suggests that if the consent process for complex ongoing investigations - such as 278 
genomic testing - is judged solely on participants’ ability to accurately recall the decisions they 279 
took; it would need rethinking. For example, some participants could not remember, or 280 
incorrectly remembered, whether they had asked for AFs to be looked for. This is in keeping 281 
with a previous interview study with rare disease participants from a genome sequencing 282 
project(22), where the study team demonstrated that interviewees who thought they had 283 
declined AFs – and stated their reasoning behind this decision – had actually consented to 284 
receive AFs during the consent process. Moreover, 61% of our survey participants thought that 285 
AFs would tell them about ‘all kinds of possible risks’, rather than a narrow menu of serious 286 
conditions for which screening and/or treatment is likely to be available. Whilst thinking AFs 287 
might be broader than they are is not necessarily harmful, it is concerning that some 288 
interviewees - who expressed that they had not chosen to find out about AFs - had ostensibly 289 
chosen to do so when they provided consent for the project (and vice-versa). Rigidly sticking 290 
to patient’s binary answers to complex questions made some time ago, when there is little 291 
evidence that these answers reflect what they think today, may prove to be ill-advised(23). 292 
 293 
This in turn presents a challenge to the usefulness of consent forms; what patients thought they 294 
had chosen, and what they had indicated at the time of consent, were at times different. This 295 
suggests that when difficult ethical questions arise in the clinic, for example if a health risk is 296 
inadvertently found during genomic testing where a patient could mitigate the risk if they knew 297 
about it, we should not exclusively decide what to do by deferring to their previous consent 298 
forms. The consent process should be seen as a continuum of ongoing communication to allow 299 
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for changes over time(24), and whilst the consent form might be a useful proxy for what a 300 
patient might currently think, our data suggests that this should not be assumed without 301 
question. It can be argued that inasmuch as a participant understands the decisions that they 302 
are making at the time of a consent conversation, their consent is ‘informed’, regardless of 303 
whether they can recollect the decisions they made. However, our research shows that people 304 
who have made decisions during the consent process would not necessarily endorse the 305 
decision that they took at that time when asked again at a later date. Whilst this does not 306 
necessarily mean that their original decision was not ‘informed’, it does mean that HPs should 307 
be aware that there is potentially a temporal aspect to ‘informed consent’, and a decision taken 308 
some time ago may not accurately reflect the decision that a participant might take today. 309 
 310 
Our study also raises the question of how consent conversations functioned during the 100kGP 311 
– why did some participants apparently make different decisions to what they thought they 312 
had? Some people might have changed their mind over the months since joining the project, or 313 
perhaps had not engaged with questions in the same way when they were raised during their 314 
consent conversation, as when they explored them during their in-depth interview. The 100kGP 315 
consent process packed in a large quantity of information(4), and our data suggest that on the 316 
whole this was not seen as problematic by patients. There is a tension between providing 317 
sufficient information such that people can make informed decisions about genomic testing, 318 
and providing so much information that they cannot meaningfully engage with some of these 319 
decisions(3).  320 
 321 
Our research indicates a potential discrepancy between the choices participants’ might have 322 
documented on their consent forms for 100kGP regarding AFs, and the choices that they 323 
actually intended to make. Perhaps discussions about AFs needed more prominence during 324 
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consent conversations, potentially at the expense of detailed discussion of issues like data 325 
security(25). Whilst it is clearly very important that participants have access to detailed 326 
information about the latter, if they find it relevant and useful, we feel it is important to consider 327 
how to provide information on these topics without overshadowing discussion of other issues 328 
that patients might consider more important. In complex situations like these, whilst the 329 
decisions needing discussion may be broad in scope, consent discussions may need to be 330 
tailored in the sense that they need to focus on the aspects of greatest concern to the particular 331 
individuals making these decisions. This will mean HPs moving away from aiming to cover 332 
everything in a tick box-type model. 333 
 334 
Informing patients about genomic tests 335 
Some participants had not considered that their results might be relevant to their blood 336 
relatives, and many participants had unrealistic expectations of the likelihood of receiving a 337 
diagnosis or AF. The majority of survey participants thought it was likely that they or their 338 
family member would receive a diagnosis from the project, whilst the actual figures are likely 339 
to be much lower. These results are supported by findings from a survey of rare disease 100kGP 340 
participants conducted by Genetics Alliance and Genomics England who found a mismatch 341 
between participant’s hopes of taking part and what has actually been delivered so far by the 342 
project(2). Media discourse around genomics and personalised medicine - that tends to present 343 
the usefulness of genomic technology in a strongly positive light - may have contributed to 344 
creating high expectations as to what the 100kGP was able to deliver(26). Our research 345 
emphasises the importance of highlighting the potential limitations of genomic testing during 346 
the consent process – many people will not receive a genomic diagnosis, or their results may 347 
be unclear and difficult to interpret(5).  348 
 349 
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The benefits of genomic testing, especially testing for pre-symptomatic treatable diseases, will 350 
be realised partly by patients sharing this information with their relatives(27). Our findings 351 
reiterate the importance of ensuring that people having genomic testing are made aware that 352 
their decisions, and their results, may have relevance for their blood relatives. One participant 353 
expressed this particularly clearly: “If someone had said that to me, go home and speak to your 354 
family about it, then I would have thought “oh yeah actually”, but it’s only you speaking about 355 
it now that I actually stop to think about them”. It appears paradoxical that the rare disease 356 
participants were taking part in a project with their family members but did not fully recognise 357 
that results from the project might have relevance for others in their family. Participants seemed 358 
to have compartmentalised certain findings, maybe this helped them understand this complex 359 
project. Our survey confirmed that the majority of participants had not told their relatives about 360 
their decision about AFs. Whilst this does not necessarily mean that they would not go on to 361 
inform their relatives if an AF was found, earlier awareness that genomic testing could reveal 362 
information of familial relevance might make this process easier (28). Previous research 363 
indicates that patients generally recognise the importance of sharing genetic information with 364 
family members, especially regarding risks of diseases that can be prevented or treated(9), 365 
although, in practice, some patients struggle to inform their at-risk relatives in a timely 366 
fashion(29). We suggest that during the consent conversations for genome sequencing, patients 367 
should be encouraged to consider talking to their relatives about their decision to have a test.  368 
 369 
Implications for the NHS Genomic Medicine Service 370 
Despite the inaccurate recollection and misperceptions about the project, participants generally 371 
felt satisfied with their decision to take part in the 100kGP. Many participants expressed trust 372 
in the project and the HPs involved, and were unconcerned even when it was pointed out that 373 
some of the decisions they made during the consent process were different to what they had 374 
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previously thought. This finding may be connected to trust that the project would ‘do the right 375 
thing’ regardless. If this is the case, then the project has a responsibility to continue acting in a 376 
trustworthy manner, which may involve adapting the existing consent process to include 377 
determining whether participants who consented to have AFs looked for are still happy to 378 
receive them. 379 
 380 
Our study suggests that whilst consent conversations for the 100kGP did not always succeed 381 
at informing participants and eliciting what they really thought about particular questions, they 382 
were fulfilling wider functions such as reinforcing trust(21). Some 100kGP participants will 383 
have chosen to take part based on trust rather than on carefully weighing and considering large 384 
volumes of information(20). This underlines the importance of the newly formed NHS 385 
Genomic Medicine Service focussing on trustworthiness by reflecting on empirical findings, 386 
from studies such as ours, and continuing to refine and research the consent process(30). This 387 
trust needs to be maintained by ensuring that genomic testing takes place within a system of 388 
processes, where patients can be confident that their data will be protected appropriately, and 389 
that their preferences will guide the sorts of results that might be looked for(3, 31). Part of this 390 
process might involve ensuring that patients are not given the illusion of clear-cut choices if 391 
these might later be hard to interpret and honour. 392 
 393 
We argue that in the context of the NHS Genomic Medicine Service, consent conversations 394 
need to be more open-ended(32), with participants aware that aspects of their consent might 395 
need to be revisited over time in response to changing contexts. Findings from other studies 396 
support this, suggesting that patients would like more information and more contact throughout 397 
the process of genomic testing(2). The Consent and Confidentiality guidelines in genomic 398 
medicine move towards this, offering a ‘record of discussions’ template as opposed to a consent 399 
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form(33). As genomic testing transitions from being available only via projects like the 400 
100kGP, with dedicated research time and infrastructure to support it, to being routinely 401 
offered in the NHS(31), we highlight the need to examine our practices regarding consent. This 402 
is reiterated by the Nuffield Council on Bioethics who outline the limitations of one-off consent 403 
in fast changing areas such as genomics, where outcomes are sometimes unexpected(30). 404 
Nevertheless, genetics services are still using consent forms despite a record of discussions 405 
template being recommended in a previous edition of the Consent and Confidentiality 406 
guidelines(34). Consent may not be operating in the ways that we expect, and further research 407 
is needed to explore strategies to improve patients’ engagement with, and recollection of, the 408 
key decisions they are asked to make during consent conversations about genomic testing. We 409 
plan to further explore 100kGP participant experiences of receiving their main results and AFs. 410 
  411 
Strengths and Limitations 412 
The response rate for our survey was 60% and we recruited participants from a broad range of 413 
ages and disease types. However, 15% of surveys returned had missing data. Studies reporting 414 
the experience of participating in the 100kGP often focus on participants with rare disease (2, 415 
20, 25), whereas we have also explored the experience of participants with cancer. The results 416 
presented in this study are from one GMC, so we cannot say with certainty that these findings 417 
are representative of other GMC participant experiences. However, the consent documents and 418 
training for conducting consent appointments were standardised nationally. Some of the 419 
wording in the survey could have been interpreted differently by different people (e.g. what do 420 
‘likely’ and ‘information about a diagnosis’ mean?). Due to the mixed methodology we were 421 
able to explore the findings from the survey in more detail in the interviews, to clarify points 422 
further and to explore wider topics. 423 
 424 
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CONCLUSION 425 
Seeking participant views about the 100kGP is essential for ensuring that the NHS Genomic 426 
Medicine Service evolves in an ethically-sound way, that is in a way that benefits and respects 427 
participants and their relatives as well as protecting them from potential harm. It is not 428 
surprising that a project such as this, with such diverse aims and participant groups, and blend 429 
of research and clinical aims and governance, would throw up at least some challenges. Our 430 
findings suggest that consent alone cannot bear the weight of all subsequent decisions about 431 
what findings to disclose from WGS. Consent was of central importance to the 100kGP; 432 
however, different aims were achieved through the consent process than were originally 433 
planned. Our research shows that some participants did not remember key details of decisions 434 
taken during their initial consent conversation and had expectations that differed from those 435 
the project could deliver, emphasising that genomic testing needs to happen in a context 436 
whereby these issues can be dealt with along the way. Providing participants with a copy of 437 
their consent forms, as the 100kGP did, may be a useful step in allowing people to remind 438 
themselves of the decisions they made at the time of their initial consent conversation. 439 
However, such an approach is not sufficient to conclude that a person still holds the same views 440 
now that they appeared to at the time of the consent conversation. We highlight the need for a 441 
national discussion about the role of consent in the NHS Genomic Medicine Service – how can 442 
we best facilitate it, and how should we respond to questions that patient consent alone cannot 443 
answer? Our paper raises the question: are participants in the 100kGP prepared for the issues 444 
that arise from not remembering or understanding discussions had and decisions made in the 445 
initial consent appointments?  446 
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